J&J | JNJ - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.58B 316M 2026-03
Abbott USD 3.27B 138M 2026-03
Amgen USD 1.58B 354M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Baxter International USD 728M 33M 2026-03
Bayer EUR 3.7B 356M 2026-03
Becton, Dickinson and Co. USD 1.21B 180M 2026-03
Biogen USD 554.3M 128.2M 2026-03
Boston Scientific USD 1.78B 53M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
CONMED USD 141.7M 25.06M 2026-03
Cooper Companies USD 676.2M 303.1M 2026-03
Dexcom USD 349.7M 49.8M 2026-03
Edwards Lifesciences USD 522.2M 80.7M 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Globus Medical USD 297.77M 20.7M 2026-03
Insulet USD 317.2M 14.2M 2026-03
Integra LifeSciences USD 178.24M 21.79M 2026-03
Intuitive Surgical USD 613.3M 73.8M 2026-03
J&J USD 6.03B 719M 2026-03
Medtronic 2.96B 9M 2025-12
Merck USD 2.67B 180M 2026-03
Merit Medical Systems USD 110.47M 4.36M 2026-03
Novartis USD 3.14B 296M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.33B 419M 2026-03
Stryker USD 2.15B 17M 2026-03
Tandem Diabetes Care USD 99.86M 5.34M 2025-12
Teva Pharmaceutical Industries USD 1000M 120M 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03
Zimmer Biomet Holdings USD 849.9M 5.8M 2026-03
Zoetis USD 588M 31M 2026-03